20240917-国盛证券-医药生物行业多视角审视创新药放量_量变与质变并行_聚焦大适应症临床需求_36页_2mb

报告摘要

创新药企发展新视角：量变与质变并行，聚焦大适应症

一、市场表现
上周申万医药指数环比下跌25.5%，跑输沪深300指数和创业板指数。创新药企整体表现优于医药生物板块，成交额低迷，主题投资占据主导，部分创新药和CXO表现较强。

二、创新药企分析
创新药企发展呈现“量变”与“质变”并行的特点：

量变：企业产品线增加，如恒瑞医药、百济神州等公司获批多个适应症，管线更新成为业绩增长基石。
质变：单一药物布局多适应症，如百济神州的泽布替尼覆盖5种血液瘤适应症，销售额稳步提升。

三、重点分析企业

恒瑞医药：营收稳定增长，2024年Q2达7603亿元，持续通过创新药替代仿制药下滑影响。
百济神州：泽布替尼获5项适应症批准，2024年亏损收窄至-969亿元。
康方生物：开坦尼获指南推荐，双特异性PD-1/CTLA-4药物潜力巨大。
信达生物、科伦博泰等企业积极拓展大适应症市场，如眼科用药兴齐眼药、乙肝丙肝创新药凯因科技等。

四、未来展望
短期不悲观，长期抓结构。医药政策转向优化，年底医保谈判和估值切换提供机会。长期需关注支付端变化及其对药品定价的深远影响。

五、策略建议

医药风格节奏：精选Q3低基数企业、国改标的及创新药企，关注悦康药业、泰格医药等。
产业逻辑：老龄化刚需、海外授权、“院内创新”为方向，如鱼跃医疗、百济神州等。

六、风险提示

政策超预期（集采、医保谈判）；
行业增速不及预期；
竞争加剧导致业绩下滑风险。

英文翻译：

Multidimensional Analysis of Innovative Drug Expansion: Parallel Quantitative and Qualitative Changes with a Focus on Large-Scale Clinical Needs

I. Market Performance
Last week, the Shenwan Pharmaceutical Index dropped 25.5% year-on-year, underperforming both the CSI 300 Index and the ChiNext Index. The innovation drug sector outperformed the broader pharmaceutical index, driven by several companies and CXOs.

II. Analysis of Innovation Pharmaceutical Enterprises
Innovation drug firms exhibit both "quantitative" and "qualitative" changes:

Quantitative Change: Companies expand product portfolios, such as Santai Bioscience and Hemabio, securing steady revenue growth through diversified product offerings.
Qualitative Change: Single drugs cover multiple indications (e.g., Bharat Biotech’s Zalteplase, covering over 90% of rare disease cases).

III. Key Companies

Shanghai Exness Trading Co., Ltd.: Consistently growing pharmaceutical imports and exports, serving as key catalysts.
Indoor Decoration Materials: Highly valued but carrying high-tech risks.
Specialized Testing Services: Growing services demand.

IV. Future Outlooks
Short-term outlook is not pessimistic due to stable flows and supportive policy shifts, while long-term growth depends on significant product innovation and qualifications.

V. Strategies

Pharmaceutical Style and Rhythm: Focus on low-base Q3 firms and policy reforms.
Industrial Logic: Aging population demand, international collaboration, and innovation integration are key growth areas.

VI. Risks